Fatty acids are an important class of signaling molecules regulating key aspects of whole body metabolism and physiology. In this issue, Yore et al. report a group of branched fatty acid esters of hydroxy fatty acids that regulate insulin secretion and glucose uptake through the activation of GPR120.
Cooking up drugs with the potential to prevent or treat obesity and type 2 diabetes has proven a challenge that might have even been too great for Walter White, the resourceful chemist of the TV's Breaking Bad. New discoveries focusing on fat cells, however, may offer hope. White adipose tissue, by virtue of its ability to store energy, is central to the regulation of lipid and glucose homeostasis during the fed and fasted state. Recently, fat has also received attention for its ability to increase energy expenditure and counteract the development of obesity and type 2 diabetes. This has been driven mainly by the identification of functional human brown adipose tissue. Nevertheless, dysfunctional white adipose tissue remains one of the primary causes of insulin resistance associated with obesity and the metabolic syndrome. Pharmacological interventions to treat or reverse the consequences of obesity and type 2 diabetes might be more likely to succeed if their target includes white adipose tissue function. In the current issue of Cell, Yore et al. (2014) offer such a functional target with the identification of a new class of branched fatty acid esters of hydroxy fatty acids (FAHFA). FAHFA are synthesized in response to Glut4-mediated glucose uptake and activation of the transcription factor ChREBP (Carbohydrate-responsive element-binding protein) in white adipocytes and released in the blood to enhance insulin secretion and increase insulin-stimulated glucose uptake into adipose tissue through the activation of Gpr120 (Figure 1 ) (Yore et al., 2014) . Hence, the authors extend the repertoire of white adipocyte endocrine factors, as well as those from other tissues, to include a previously unrecognized class of fatty acid esters that function as important regulators of glucose homeostasis.
Regulation of glucose and lipid homeostasis is a key function of adipocytes, one that critically depends on insulin-mediated glucose uptake by Glut4. In line with this, downregulation of Glut4 in adipose tissue is one of the earliest events in the pathogenesis of insulin resistance and type 2 diabetes. The key role of this pathway is underscored by the ability of adipose tissue selective overexpression of Glut4 (AG4OX mice) to rescue glucose intolerance and insulin resistance in muscle-specific Glut4 knockout mice (Carvalho et al., 2005) . However, contrary to the general association of increased free fatty acids with insulin resistance, these mice show improved insulin sensitivity and increased serum-free fatty acids. Subsequently, Herman et al. (2012) established that ChREBP mediates the beneficial effects of enhanced Glut4-mediated glucose uptake in adipocytes by activating de novo lipogenesis. This suggests that in addition to the release of metabolically unfavorable fatty acid metabolites like long chain fatty acid acyl-CoA, diacylglycerol and ceramides, adipocytes could secrete lipid species that are metabolically beneficial, a notion supported by data from the laboratory of Gokhan Hotamisligil, who identified palmitoleate as an adipose-derived lipid hormone improving insulin action in muscle and liver (Cao et al., 2008) . Thus, in addition to the various hormones and cytokines released from adipocytes, lipids, as lipokines, could act as important regulators of whole body metabolism.
To test their hypothesis, Yore et al. set out to measure adipose lipids in AG4OX mice using an advanced, untargeted mass spectrometry lipidomics approach, from which they discover a previously unidentified class of fatty acid-hydroxy fatty acids (FAHFAs), consisting of 16 different members. Among this group, palmitic acid-hydroxy stearic acids (PAHSA) are the most highly upregulated fatty acids in adipose tissue of AG4OX mice, which led the authors to investigate the biological regulation and activity of PAHSAs.
There are a total of eight different PAHSA isomers in mouse tissues, and each isomer is defined by the position of the ester at a different carbon of the hydroxystearic acid (HSA) in the PAHSA structure. PAHSA levels are reduced with diet-induced obesity and insulin resistance in both mice and humans. These data alone are significant, because they establish PAHSAs as new biomarkers for insulin resistance. Moreover, the correlation between high PAHSA levels and insulin sensitivity prompted the authors to measure the effects of these lipids in vivo. Oral delivery of 9-PAHSA and 5-PAHSA to mice enhances glucose tolerance through their ability to bind to and activate the Gpr120 long-chain fatty acid receptor. In line with this potential function as a natural Gpr120 ligand, PAHSAs enhance insulin secretion through their action on pancreatic islets and Glp-1-secreting intestinal enteroendocrine cells. In addition, similar to the effects of u-3 fatty acids, PAHSAs reduce lipopolysaccharide-and high-fat-dietinduced inflammation. Further evidence for a connection between PAHSAs and GPR120 is established by demonstrating that insulin-stimulated Glut4 translocation and glucose uptake in adipocytes requires PAHSA-induced GPR120 signaling.
Overall, they not only describe the origin and regulation of an entirely new class of signaling metabolites during different metabolic states, like fasting and high fat diet feeding, but also identify Gpr120 as a FAHFA receptor.
Yore et al. establish PAHSAs as Gpr120 ligands, defining their physiological functions in increasing insulin secretion and insulin-stimulated glucose transport, thereby modulating glucose homeostasis. However, some of the observed results might not be fully explained by signal mediation through Gpr120. The regulation of Glp-1 secretion, for example, has been associated with both activation of Gpr120 and the functionally closely related Gpr40 (Milligan et al., 2014) . Moreover, recently Oh da et al. (2014) described a Gpr120-selective agonist that confers an improvement of glucose tolerance similar to PAHSAs and fails to directly induce Glp-1 secretion. Thus, using Gpr120-deficient animal models it will be interesting to determine if PAHSAs are endogenous Gpr40 ligands too. PAHSAs could also enable the development of powerful coagonists that would simultaneously activate both receptors and, similar to what we have shown for GIP/Glp-1 dual incretin agonists (Finan et al., 2013) , utilize the positive consequences of these receptor activities while reducing the risks of ligand resistance and toxicity. This seems especially important for the activation of Gpr40, as evidenced by the recent failure of a clinical phase III study using Fasiglifam (TAK-875) due to concerns about liver toxicity (Milligan et al., 2014) .
In addition to their role in Glp-1 secretion, PAHSAs are also directly associated with insulin secretion from pancreatic b-cells. However, recent data suggest that activation of Gpr120 to regulate insulin secretion may be mediated mainly through inhibition of somatostatin release from d-cells rather than direct action on b-cells, further indicating a potential agonistic action of PAHSAs on Gpr40 (Stone et al., 2014) , or other fatty acid receptors.
Aside from their pharmacological action, the exact pathways and enzymes responsible for the production and release of FAHFAs remain unknown but are an important piece of the puzzle. The current study demonstrates that enzymes within adipose and liver lysates produce similar amounts of PAHSAs from exogenous substrates, yet tissue levels are dramatically different, indicating that the substrate might be the rate-limiting factor determining tissue abundance. The synthesis of FAHFAs in nonadipose tissues, suggests that FAHFAs, like other signaling lipids, (Gillum et al., 2008; Rodrí-guez de Fonseca et al., 2001) , are not specific to adipocytes but can be produced and released from a variety of tissues. Thus, FAHFAs from nonadipose tissues could also contribute to the endocrine effects of these lipids. Yore et al. show that PAHSA levels change dramatically within adipose tissue upon fasting and high-fatdiet feeding. Conversely, overall serum PAHSA levels remain unchanged upon these interventions, indicating that individual PAHSA isomers might show selective, nonredundant functions to mediate changes in Glp-1 and insulin secretion.
To date, proteins and peptides remain the focus of endocrinologists who seek to decipher the communication pathways between organs and develop new therapeutic strategies. However, new structurally diverse sets of metabolites, either from within the body or from gut microbiota, have emerged as important regulators of metabolism. The identification of branched fatty-acid-esters of hydroxyfatty-acids as endocrine factors highlights the significance of metabolomics studies in revealing new targets for the treatment of type 2 diabetes and the metabolic syndrome beyond genomics and proteomics. Identifying other important, and likely existing, bioactive metabolites and using that knowledge to develop personalized therapy options to treat obesity and metabolic syndrome are an opportunity we can't afford to miss. For now, white adipose tissue has taught us another important (bio-)chemical lesson we suspect even Walter White would have found quite fascinating.
Figure 1. PAHSAs Regulate Multiple Components of Glucose Homeostasis
In response to Glut4-mediated glucose uptake and ChREBP dependent mechanisms palmitic acidhydroxy stearic acid (PASHA) isomers are produced and secreted from adipose tissue in response to Glut4-mediated glucose uptake and activation of ChREBP. PASHAs can activate Gpr120 on adipocytes and enhance insulin-mediated glucose uptake via Glut4. Serum PASHAs also show endocrine effects that enhance insulin secretion via activation of Gpr120 from pancreatic islets or via intestinal L-cells that induces Glp-1 secretion. The exact cellular types (b-or d-cells) in pancreatic islets targeted by PASHAs remain to be determined. Thus, increased release of PAHSAs regulates glucose homeostasis directly on adipocytes through increased insulin secretion and could thereby also indirectly impact on insulin action in skeletal muscle and liver.
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Nuclear pore assembly can go awry, but how the cell handles defective intermediates has been an ongoing question. In this issue, Lusk and colleagues describe a surveillance pathway during nuclear pore assembly and, in doing so, identify a new role for proteins that function at the endosome and plasma membrane.
Cells eliminate defective products through quality control mechanisms to ensure that biochemical pathways operate smoothly. One well-studied example of quality control is endoplasmic reticulum-associated degradation (ERAD), an intricate process by which secretory and membrane proteins that fail to fold properly within the confines of the endoplasmic reticulum are extruded into the cytosol for disposal by proteasomes (Ruggiano et al., 2014) . ERAD is but one way in which cells guard against abnormal accumulations of proteins that might be nonfunctional or could potentially be dangerous. More pathways for quality control, however, remain to be discovered. In this issue of Cell, Webster et al. describe a new quality control pathway to eliminate nascent nuclear pore complexes (NPCs) that have failed to assemble properly and, in doing so, they unexpectedly broaden the realm of activities for a protein machinery that was originally discovered to function at endosomes.
Hundreds of NPCs perforate the double-membrane barrier created by the nuclear envelope to form aqueous channels that connect the cytoplasm with the interior of the nucleus. Given their sheer abundance, NPCs are constantly undergoing assembly in proliferating cells (Fernandez-Martinez and Rout, 2009 ). Humans and other eukaryotes undergo open mitosis during which NPCs are disassembled at the onset of mitosis into their constituent proteins, the nucleoporins. At the end of mitosis, these nucleoporins reassemble into new NPCs in the newly formed nucleus established in each daughter cell. Given that mitosis effectively doubles the amount of nuclear membrane, NPCs must also be assembled with newly synthesized nucleoporins since assembly with recycled nucleoporins is not sufficient to maintain the density of NPCs needed in the nuclei of daughter cells. NPC assembly is even more reliant on newly synthesized nucleoporins in the budding yeast Saccharomyces cerevisiae, which has a closed mitosis where the nuclear membrane remains intact, and pre-existing NPCs do not undergo disassembly.
In humans and yeast, defects in NPC assembly can result in aggregates of nucleoporins that decrease nuclear integrity, which is linked to a reduction in cellular replicative lifespan (Fernandez-Martinez and Rout, 2009) . In this issue of Cell, the study by Webster et al. (2014) shows that in yeast, misassembled NPCs accumulate in a storage compartment they term the SINC, for storage of improperly assembled nuclear pore complexes. SINCs are preferentially retained in mother yeast cells during mitosis. This apparent act of altruism prevents defective NPCs from being passed on to progeny but saddles parental cells with the prospect of decreased NPC utility as they age. Indeed, the accumulation of SINCs in mother yeast cells correlates with a reduction in nucleocytoplasmic transport.
Unexpectedly, defective NPC assembly intermediates can avoid the SINC altogether through a pathway that involves the endosomal sorting complexes required for transport (ESCRTs). As their name implies, ESCRTs were originally identified because of their function at endosomes. In the canonical ESCRT pathway, five distinct protein complexes cooperate in the creation of vesicles that bud into the endosome lumen, and these intralumenal vesicles are destroyed in the interior of the lysosome upon endolysosomal fusion (Figure 1) . However, ESCRTs have since been found to operate at the plasma membrane, where they are
